Hero Image

About Us

Our history

The Development Journey of SightGlass Vision and DOT™ Lenses

2007

Scientific Origins of DOT™ Lenses: Contrast Theory Takes Shape

A genetics discovery by Professors Jay and Maureen Neitz led to the hypothesis that contrast signaling in the retina may play a role in myopia development,1 laying the scientific foundation for DOT™ lenses.

2016

SightGlass Vision Founded to Translate Scientific Theory into Applications for Myopia Management

SightGlass Vision was founded in the United States, with a mission to translate contrast theory into innovative optical solutions for myopia management in children and adolescents.

2018

DOT™ Lenses Enter the Stage of Gold-Standard Clinical Evidence Generation2-4

SightGlass Vision launched the four-year CYPRESS study across 14 clinical sites in North America, including the United States and Canada, to systematically evaluate the safety and efficacy of DOT™ lenses.

2021

A New Stage of Commercial Development Begins, with DOT™ Lenses Launched for the First Time

CooperVision, Inc. and Essilor International announced a joint venture to acquire SightGlass Vision. In the same year, DOT™ spectacle lenses for myopia control were launched in the Netherlands, marking the official entry of the lenses into commercial application.

2022

DOT™ Lenses Expand into New Markets as Clinical Results Are Published

DOT™ lenses launched in additional markets, including China. In the same year, the 12-month results of the North American CYPRESS study were published, providing clinical evidence supporting the myopia management efficacy of DOT™ lenses.

2023

New Clinical Study Initiated to Further Evaluate DOT™ Lenses

The CATHAY study was initiated across five leading hospitals in China to further evaluate the performance of DOT™ lenses in children, adding to the growing body of clinical research supporting their use in managing myopia progression.

2024

Growing Clinical Evidence of DOT™ Lenses

Research on the visual impact of DOT™ lenses was published,5 alongside four-year CYPRESS results.6

2025

DOT™ Lenses Expand Globally as Wearer Base Reaches One Million

SightGlass Vision continued to showcase DOT™ lenses on academic platforms internationally, as one-year CATHAY results are published supporting the safety, efficacy, and wearing experience of the lenses.3 As of August 2025, one million children had worn DOT™ lenses,7 with real-world application experience continuing to accumulate. Early access also launched in the U.K., further expanding availability, with DOT™ lenses commercially available in Canada, China, Israel, and Spain.

2026

New Clinical Evidence Announced

Two-year results of the CATHAY study were announced, showing that DOT™ lenses for myopia control saved more than 1D of progression on average after two years among Chinese children aged 6 to 10.8†

2026 to Present

DOT™ Lenses Wearer Base Surpasses Two-Million Milestone

DOT™ spectacle lenses worn by two million children worldwide, less than one year after reaching the one million wearer milestone, reflecting continued growth in the number of children wearing the lenses.9

Who we are

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research based on the unique contrast theory.

Its unique Diffusion Optics Technology™️ is based on these ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children.

The treatment has completed the three years pivotal multisite clinical study.

Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

Discover our career opportunities

Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.

†Prescribed DOT lens wear time was 10 hours per day. LS Mean progression difference of 1.01D between test and control groups.

SightGlass Vision™ products are not available for sale in all countries, including the United States.

 

1. Neitz M et al. Insight from OPN1LW Gene Haplotypes into the Cause and Prevention of Myopia. Genes. 2022;13(6):942

2. RapponJ, Neitz J, Neitz M, et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time wearers. Invest Ophthalmol Vis Sci 2022 :e001790.

3. Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.

4. Hariton E, Locascio JJ. Randomised controlled trials – the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG. 2018 Dec;125(13):1716.

5. Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.1.

6. Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): BMJ Open Ophthalmology 2024;9:e001790;

7. SGV data on file 2025: 2024/25 sales data and repeat purchase rates; reflects global usage across multiple regions.

8. SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172 (6-10 years: 117), 5 sites in China). Overall patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional singlevision lenses to evaluate their continued safety and efficacy in Chinese children.

9. SGV data on file 2026: 2024-26 sales data and repeat purchase rates; reflects global usage across multiple regions. Internal sales report, please do check with SGV team for more details.